MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 228 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,250,316 | +2510.3% | 172,900 | +4230.1% | 0.07% | +2366.7% |
| Q1 2023 | $967,344 | -34.9% | 3,993 | -82.5% | 0.00% | -50.0% |
| Q3 2022 | $1,487,000 | -38.1% | 22,876 | -24.0% | 0.01% | -45.5% |
| Q3 2021 | $2,402,000 | -54.4% | 30,100 | -61.9% | 0.01% | -74.4% |
| Q1 2020 | $5,267,000 | +100.1% | 78,900 | +158.5% | 0.04% | +168.8% |
| Q3 2019 | $2,632,000 | -56.6% | 30,521 | -47.3% | 0.02% | -50.0% |
| Q2 2019 | $6,068,000 | +133.3% | 57,900 | +178.8% | 0.03% | +166.7% |
| Q1 2019 | $2,601,000 | -56.5% | 20,767 | -60.8% | 0.01% | -58.6% |
| Q4 2018 | $5,974,000 | -70.6% | 53,000 | -44.1% | 0.03% | -65.5% |
| Q3 2018 | $20,300,000 | +335.6% | 94,800 | +137.6% | 0.08% | +342.1% |
| Q1 2018 | $4,660,000 | -57.7% | 39,900 | -66.8% | 0.02% | -60.4% |
| Q4 2017 | $11,015,000 | – | 120,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |